GDF-15、半乳糖凝集素3、可溶性ST2与CKD患者死亡及心血管事件风险
该观察性队列研究纳入883例CKD患者,基线平均eGFR为49±19mL/min/1.73m2。校正人口学、心血管危险因素和肾功能后,GDF-15、Gal-3、sST2每升高1个标准差均与全因死亡显著相关,仅GDF-15与心衰事件相关,三者均与动脉粥样硬化性心血管事件无显著关联。
要点
- GDF-15、Gal-3、sST2升高与CKD患者全因死亡风险增加独立相关。
- 仅GDF-15升高与心衰住院风险增加相关。
- 三者均与动脉粥样硬化性心血管事件无显著关联。
核心结论
- CKD患者循环GDF-15、Gal-3、sST2浓度较高与全因死亡风险增加相关。
- GDF-15升高还与心衰事件发生率增加相关。
- 三种生物标志物均与动脉粥样硬化性心血管事件无显著关联。
研究设计与样本
- 观察性队列研究,纳入Seattle Kidney Study或C-PROBE两个多中心CKD队列的883例CKD患者。
主要发现
- GDF-15每升高1-SD,全因死亡aHR为1.87(95%CI 1.53-2.29)。
- Gal-3每升高1-SD,全因死亡aHR为1.51(95%CI 1.36-1.78)。
- sST2每升高1-SD,全因死亡aHR为1.36(95%CI 1.17-1.58)。
- GDF-15每升高1-SD,心衰事件HR为1.56(95%CI 1.12-2.16)。
- GDF-15、Gal-3、sST2与动脉粥样硬化性心血管事件均无显著关联。
临床怎么用
- 在CKD患者中检测GDF-15、Gal-3、sST2有助于识别全因死亡和心衰高风险个体。
- GDF-15对心衰风险分层价值更突出,但尚不能替代现有临床评估。
局限性
- 心衰和动脉粥样硬化性心血管事件发生率较低。
- 研究为观察性设计,不能确立因果关系。
- 生物标志物与CVD关联的机制尚待进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Inflammation, cardiac remodeling, and fibrosis may explain in part the excess risk for cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Growth differentiation factor 15 (GDF-15), galectin 3 (Gal-3), and soluble ST2 (sST2) are possible biomarkers of these pathways in patients with CKD. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: Individuals with CKD enrolled in either of 2 multicenter CKD cohort studies: the Seattle Kidney Study or C-PROBE (Clinical Phenotyping and Resource Biobank Study). EXPOSURES: Circulating GDF-15, Gal-3, and sST2 measured at baseline. OUTCOMES: Primary outcome was all-cause mortality. Secondary outcomes included hospitalization for physician-adjudicated heart failure and the atherosclerotic CVD events of myocardial infarction and cerebrovascular accident. ANALYTIC APPROACH: Cox proportional hazards models used to test the association of each biomarker with each outcome, adjusting for demographics, CVD risk factors, and kidney function. RESULTS: Among 883 participants, mean estimated glomerular filtration rate was 49±19mL/min/1.73m2. Higher GDF-15 (adjusted HR [aHR] per 1-SD higher, 1.87; 95% CI, 1.53-2.29), Gal-3 (aHR per 1-SD higher, 1.51; 95% CI, 1.36-1.78), and sST2 (aHR per 1-SD higher, 1.36; 95% CI, 1.17-1.58) concentrations were significantly associated with mortality. Only GDF-15 level was also associated with heart failure events (HR per 1-SD higher, 1.56; 95% CI, 1.12-2.16). There were no detectable associations between GDF-15, Gal-3, or sST2 concentrations and atherosclerotic CVD events. LIMITATIONS: Event rates for heart failure and atherosclerotic CVD were low. CONCLUSIONS: Adults with CKD and higher circulating GDF-15, Gal-3, and sST2 concentrations experienced greater mortality. Elevated GDF-15 concentration was also associated with an increased rate of heart failure. Further work is needed to elucidate the mechanisms linking these circulating biomarkers with CVD in patients with CKD.
引用
- Tuegel C, Katz R, Alam M, et al. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. Am J Kidney Dis. 2018. PMID: 29866459. doi:10.1053/j.ajkd.2018.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。